How many insider trades does FilingIQ track for LNSR?

FilingIQ tracks 98 Form 4 insider transactions for LNSR (LENSAR, Inc.), covering filings from Sep 29, 2020 onwards. 9 of those were filed in the last 90 days.

Are LNSR insiders net buyers or net sellers?

Across the full Form 4 history for LNSR, 30 transactions (31%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does LNSR insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is LNSR in?

LENSAR, Inc. (LNSR) is classified in the Healthcare sector, specifically Medical Devices, with a current market capitalisation of $139.63M.

LNSR insider trading

NasdaqCM Healthcare

LENSAR, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

31% / 0%

Market cap

$139.63M

About LENSAR, Inc.

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System. The company offers LENSAR Laser System which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

Company website: www.lensar.com

LNSR insider activity at a glance

FilingIQ has scored 98 insider transactions for LNSR since Sep 29, 2020. The most recent filing in our index is dated May 6, 2026.

Across the full history, 30 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on LNSR insider trades is 51.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live LNSR trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for LNSR?: FilingIQ tracks 98 Form 4 insider transactions for LNSR (LENSAR, Inc.), covering filings from Sep 29, 2020 onwards. 9 of those were filed in the last 90 days.
Are LNSR insiders net buyers or net sellers?: Across the full Form 4 history for LNSR, 30 transactions (31%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does LNSR insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is LNSR in?: LENSAR, Inc. (LNSR) is classified in the Healthcare sector, specifically Medical Devices, with a current market capitalisation of $139.63M.

Methodology & sources

Every LNSR insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.